GRI Bio Statistics
Total Valuation
GRI Bio has a market cap or net worth of $6.61 million. The enterprise value is $2.00 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
Earnings Date | Nov 14, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
GRI Bio has 8.93 million shares outstanding. The number of shares has increased by 4,890.31% in one year.
Current Share Class | 8.93M |
Shares Outstanding | 8.93M |
Shares Change (YoY) | +4,890.31% |
Shares Change (QoQ) | +590.51% |
Owned by Insiders (%) | 0.09% |
Owned by Institutions (%) | 1.54% |
Float | 8.92M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.02 |
P/TBV Ratio | 1.81 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.10, with a Debt / Equity ratio of 0.04.
Current Ratio | 3.10 |
Quick Ratio | 2.77 |
Debt / Equity | 0.04 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -280.72% and return on invested capital (ROIC) is -171.75%.
Return on Equity (ROE) | -280.72% |
Return on Assets (ROA) | -105.28% |
Return on Capital (ROIC) | -171.75% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.07M |
Employee Count | 4 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.03% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -98.03% |
50-Day Moving Average | 0.77 |
200-Day Moving Average | 2.83 |
Relative Strength Index (RSI) | 47.66 |
Average Volume (20 Days) | 373,529 |
Short Selling Information
The latest short interest is 122,021, so 1.37% of the outstanding shares have been sold short.
Short Interest | 122,021 |
Short Previous Month | 205,970 |
Short % of Shares Out | 1.37% |
Short % of Float | 1.37% |
Short Ratio (days to cover) | 0.10 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -8.31M |
Pretax Income | -12.77M |
Net Income | -8.26M |
EBITDA | -8.30M |
EBIT | -8.31M |
Earnings Per Share (EPS) | -$7.90 |
Full Income Statement Balance Sheet
The company has $4.75 million in cash and $131,000 in debt, giving a net cash position of $4.62 million or $0.52 per share.
Cash & Cash Equivalents | 4.75M |
Total Debt | 131,000 |
Net Cash | 4.62M |
Net Cash Per Share | $0.52 |
Equity (Book Value) | 3.66M |
Book Value Per Share | 0.73 |
Working Capital | 3.61M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -12.17M |
Capital Expenditures | n/a |
Free Cash Flow | -12.17M |
FCF Per Share | -$1.36 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
GRI Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -4,890.31% |
Shareholder Yield | -4,890.31% |
Earnings Yield | -124.99% |
FCF Yield | -184.13% |
Analyst Forecast
The average price target for GRI Bio is $11.50, which is 1,454.05% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $11.50 |
Price Target Difference | 1,454.05% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on June 18, 2024. It was a reverse split with a ratio of 0.0769231:1.
Last Split Date | Jun 18, 2024 |
Split Type | Reverse |
Split Ratio | 0.0769231:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |